Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.

doi:10.1038/gim.2018.44

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.

Genetics in medicine : official journal of the American College of Medical Genetics - 1 Dec 2018

Girardi Fabio, Barnes Daniel R, Barrowdale Daniel, Frost Debra, Brady Angela F, Miller Claire, Henderson Alex, Donaldson Alan, Murray Alex, Brewer Carole, Pottinger Caroline, Evans D Gareth, Eccles Diana, Lalloo Fiona, Gregory Helen, Cook Jackie, Eason Jacqueline, Adlard Julian, Barwell Julian, Ong Kai Ren, Walker Lisa, Izatt Louise, Side Lucy E, Kennedy M John, Tischkowitz Marc, Rogers Mark T, Porteous Mary E, Morrison Patrick J, Eeles Ros, Davidson Rosemarie, Snape Katie, Easton Douglas F, Antoniou Antonis C

Abstract excerpt

PURPOSE: BRCA1/BRCA2 predictive test negatives are proven noncarriers of a BRCA1/BRCA2 mutation that is carried by their relatives. The risk of developing breast cancer (BC) or epithelial ovarian cancer (EOC) in these women is uncertain. The study aimed to estimate risks of invasive BC and EOC in a large cohort of BRCA1/BRCA2 predictive test negatives. METHODS: We used cohort analysis to estimate incidences,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRCA1 Protein

Share to BRCA2 Protein

Share to Breast Neoplasms

Share to Germ-Line Mutation

Share to Ovarian Neoplasms

Share to Risk Assessment

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 29565421
DOI: 10.1038/gim.2018.44
PMCID: PMC6033314

Genes

BRCA1
BRCA2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study.PMID 29565421Read ↗

Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.Semantic proximity Read ↗

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.Semantic proximity Read ↗

Considerations When Using Breast Cancer Risk Models for Women with Negative BRCA1/BRCA2 Mutation Results.Semantic proximity Read ↗

Breast cancer risks in women with a family history of breast or ovarian cancer who have tested negative for a BRCA1 or BRCA2 mutation.Semantic proximity Read ↗

Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.Semantic proximity Read ↗

No evidence of excess breast cancer risk among mutation-negative women from BRCA mutation-positive families.Semantic proximity Read ↗

Ovarian cancer among 8,005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative for BRCA1 and BRCA2.Semantic proximity Read ↗

Increased rate of phenocopies in all age groups in BRCA1/BRCA2 mutation kindred, but increased prospective breast cancer risk is confined to BRCA2 mutation carriers.Semantic proximity Read ↗

The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.Semantic proximity Read ↗

Prospective study of high-risk, BRCA1/2-mutation negative women: the 'negative study'.Semantic proximity Read ↗

Adjuvant systemic therapy for breast cancer in BRCA1/BRCA2 mutation carriers in a population-based study of risk of contralateral breast cancer.Semantic proximity Read ↗

Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.